Log in

NASDAQ:BGNEBeigene Stock Price, Forecast & News

$136.04
-8.22 (-5.70 %)
(As of 04/8/2020 06:00 AM ET)
Add
Compare
Today's Range
$135.11
Now: $136.04
$145.00
50-Day Range
$121.84
MA: $148.11
$173.19
52-Week Range
$113.01
Now: $136.04
$210.35
Volume259,314 shs
Average Volume361,670 shs
Market Capitalization$8.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; and CC-122, a cereblon modulator. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Read More
Beigene logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
CUSIPN/A
Phone1-345-949-4123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.21 million
Book Value$15.87 per share

Profitability

Net Income$-948,630,000.00
Net Margins-221.53%

Miscellaneous

Employees3,500
Market Cap$8.86 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


Beigene (NASDAQ:BGNE) Frequently Asked Questions

How has Beigene's stock been impacted by COVID-19 (Coronavirus)?

Beigene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BGNE shares have decreased by 6.6% and is now trading at $136.04. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Beigene?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beigene.

When is Beigene's next earnings date?

Beigene is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Beigene.

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) issued its quarterly earnings results on Monday, March, 2nd. The company reported ($6.39) EPS for the quarter, missing the Zacks' consensus estimate of ($4.53) by $1.86. The business had revenue of $56.89 million for the quarter, compared to analyst estimates of $60.25 million. Beigene had a negative net margin of 221.53% and a negative return on equity of 69.41%. The business's revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.52) EPS. View Beigene's earnings history.

What price target have analysts set for BGNE?

11 equities research analysts have issued 12-month price objectives for Beigene's shares. Their forecasts range from $165.00 to $230.00. On average, they anticipate Beigene's share price to reach $204.03 in the next year. This suggests a possible upside of 50.0% from the stock's current price. View analysts' price targets for Beigene.

Has Beigene been receiving favorable news coverage?

News headlines about BGNE stock have been trending very negative on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Beigene earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBeigene.

Who are some of Beigene's key competitors?

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Roku (ROKU), Tesla (TSLA), Adobe (ADBE), Netflix (NFLX) and Sarepta Therapeutics (SRPT).

Who are Beigene's key executives?

Beigene's management team includes the following people:
  • Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
  • Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
  • Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
  • Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
  • Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $136.04.

How big of a company is Beigene?

Beigene has a market capitalization of $8.86 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe. View additional information about Beigene.

What is Beigene's official website?

The official website for Beigene is http://www.beigene.com/.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel